GlaxoSmithKline and Theravance has posted positive results from a Phase III efficacy and safety study of fluticasone furoate/vilanterol (FF/VI) designed to support a potential filing for an asthma indication for adults in the U.S. FF/VI is approved in the U.S. for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) and to reduce exacerbations of COPD in patients with a history of exacerbations, FF/VI is not an FDA-approved treatment for ...